Condition: Lupus Nephritis · Sponsor: GlaxoSmithKline
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Baltimore, Maryland, United States | Recruiting |
| GSK Investigational Site | Charlotte, North Carolina, United States | Recruiting |
| GSK Investigational Site | Columbus, Ohio, United States | Recruiting |
| GSK Investigational Site | Hixson, Tennessee, United States | Recruiting |
| GSK Investigational Site | Marseille, France | Recruiting |
| GSK Investigational Site | Rozzano, Milan, Italy | Recruiting |
| GSK Investigational Site | Fukuoka, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06527872